Back to Results

Novelstem International Corp (NSTM)

Featured in Overvalued Stocks

NovelStem International Corp. is a development-stage biotechnology company whose work centers on stem cell-based diagnostic technology. The company says its research and commercialization efforts are aimed at applications in cancer treatment and at helping reduce resistance to chemotherapy. NovelStem International Corp., formerly known as Hollywood Media Corp., adopted its current name in September 2018. Incorporated in 1993, the company is headquartered in Boca Raton, Florida. Its common stock is quoted on OTC Markets under the symbol NSTM.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-NSTM
$0.0057
-50.4% Downside
Expensive
—
—
—
Fair
—
—
—
0.0%
August 14, 2026
0.2x
-0.3x
—
565.349 K
2.409 M
77.3%
41.4%
-4,107.2
—
-10.4%
Valuation • Fair Value

Novelstem International Corp (OTC-NSTM) Fair Value by Valuation Model

Compare the primary fair value estimate for Novelstem International Corp (OTC-NSTM) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.0057

Estimated downside of 50.4% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0.57

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.0057

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Novelstem International Corp (OTC-NSTM) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Novelstem International Corp (OTC-NSTM)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Novelstem International Corp (OTC-NSTM) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Novelstem International Corp (OTC-NSTM)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-4,107.2

Lower score that deserves closer risk review.

FCF / Net Income

-10.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Novelstem International Corp (OTC-NSTM). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Novelstem International Corp (OTC-NSTM)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 14, 2026

Days to Earnings

24

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Novelstem International Corp (OTC-NSTM), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Novelstem International Corp (OTC-NSTM) Stock Forecast & Technical Outlook

Review Novelstem International Corp (OTC-NSTM) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Novelstem International Corp (OTC-NSTM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Novelstem International Corp (OTC-NSTM) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Novelstem International Corp (OTC-NSTM) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Novelstem International Corp (OTC-NSTM) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Novelstem International Corp (OTC-NSTM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Novelstem International Corp (OTC-NSTM)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Novelstem International Corp (OTC-NSTM) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

Novelstem International Corp (OTC-NSTM) Stock FAQ

Quick answers about Novelstem International Corp (OTC-NSTM) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.0057
Estimated downside 50.4%
Valuation Rating
Overvalued
Estimated downside of 50.4%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for Novelstem International Corp (OTC-NSTM) is $0.0057. This implies an estimated downside of 50.4% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 50.4% versus the current market price.

An analyst price target for Novelstem International Corp (OTC-NSTM) is not currently available in the latest data file.

The current financial health read for Novelstem International Corp (OTC-NSTM) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Novelstem International Corp (OTC-NSTM) is August 14, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Novelstem International Corp (OTC-NSTM) is 0.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Novelstem International Corp is 565.349 K.

The current enterprise value listed for Novelstem International Corp is 2.409 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Novelstem International Corp is OTC-NSTM, and the stock is listed on OTC Markets.

Novelstem International Corp (OTC-NSTM) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Novelstem International Corp is 77.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Novelstem International Corp is 41.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on OTC Markets View more

CSL Ltd (CSLLY) CSL Ltd (CSLLY)
Swedish Orphan Biovitrum AB ADR (BIOV.F) Swedish Orphan Biovitrum AB ADR (BIOV.F)
Grifols SA ADR (GIKLY) Grifols SA ADR (GIKLY)
Bavarian Nordic A/S ADR (BVNRY) Bavarian Nordic A/S ADR (BVNRY)
Mesoblast Ltd (MEOBF) Mesoblast Ltd (MEOBF)
Galapagos NV (GLPGF) Galapagos NV (GLPGF)
Pharma Mar SAU (PHMMF) Pharma Mar SAU (PHMMF)
Biogaia AB ADR (BIOGY) Biogaia AB ADR (BIOGY)
Kuros Biosciences AG (CSBTF) Kuros Biosciences AG (CSBTF)
Clinuvel Pharmaceuticals Ltd (CLVLF) Clinuvel Pharmaceuticals Ltd (CLVLF)
Northwest Biotherapeutics Inc (NWBO) Northwest Biotherapeutics Inc (NWBO)
Spectral Med Inc (EDTXF) Spectral Med Inc (EDTXF)
Cytodyn Inc (CYDY) Cytodyn Inc (CYDY)
Innate Pharma (IPHYF) Innate Pharma (IPHYF)
Vaxart Inc (VXRT) Vaxart Inc (VXRT)
CapForce Inc (CFOR) CapForce Inc (CFOR)
Adocia SA ADR (ADOCY) Adocia SA ADR (ADOCY)
Nuo Therapeutics Inc (AURX) Nuo Therapeutics Inc (AURX)
Cell Source Inc (CLCS) Cell Source Inc (CLCS)
Protext Mobility Inc (TXTM) Protext Mobility Inc (TXTM)
MindMaze Therapeutics Holding SA (RLFTF) MindMaze Therapeutics Holding SA (RLFTF)
Sernova Corp (SEOVF) Sernova Corp (SEOVF)
Microbix Biosystems Inc. (MBXBF) Microbix Biosystems Inc. (MBXBF)
Resverlogix Corp. (RVXCF) Resverlogix Corp. (RVXCF)